Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

博优平 - NMPA Drug Approval Details

Approvals/NMPA/Dulaglutide Injection

Approved

生物制品

Dulaglutide Injection

山东博安生物技术股份有限公司🇨🇳 National Medical Products Administration

Approval Date: Aug 5, 2025
Approval ID: 8loPyWbuaED
Company: 山东博安生物技术股份有限公司
Type: 生物制品

Approval Details

Approval Id: 8loPyWbuaED
Approval Number: 国药准字S20250042
Generic Name: 度拉糖肽注射液
Generic Name En: Dulaglutide Injection
Trade Name: 博优平
Drug Type: 生物制品
Dosage Form: 注射剂
Strength: 0.75mg（0.5ml）/支（预充式注射器）
Reg Date: 2025-08-05
Company Name: 山东博安生物技术股份有限公司
Company Address: 山东省烟台市高新区科技大道39号
Production Company Name: 山东博安生物技术股份有限公司
Production Company Address: 山东省烟台市高新区纬一路8号
Company Detail Path: /organization/boan-biotech
Production Company Detail Path: /organization/boan-biotech

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Aug 5, 2025

Approval ID

8loPyWbuaED

Type

生物制品

Back to NMPA Approvals